Navigation Links
Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board
Date:2/25/2008

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that Dr. Fred Eshelman has joined the management board of Aton's parent company, Princeton Pharma Holdings LLC. Dr. Eshelman is the founder, Vice Chairman and CEO of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), an international contract research organization. Aton is a wholly owned subsidiary of Princeton Pharma Holdings LLC.

"We are delighted that Dr. Eshelman has agreed to join Princeton Pharma Holdings' management board," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is a rare individual -- both an accomplished entrepreneur and an accomplished scientist. He built a very successful enterprise from the ground up and his knowledge of product development is exceptional. His insights are going to provide tremendous value to Aton as we implement our strategic plan."

"Aton is a very interesting specialty pharmaceutical company with their focus on medically essential therapeutics and I'm impressed with the amount of progress they have made in a relatively short period of time," stated Dr. Eshelman. "I look forward to lending my experience and helping this company reach its goals."

Dr. Eshelman's expertise will be helpful as Aton continues to execute its product life cycle management strategy and expand its research program, which includes partnerships with a variety of thought leaders, major medical institutions and research organizations.

Dr. Eshelman's career has included positions as Senior Vice President of Development and Vice President of Clinical Operations for the former Glaxo, Inc., as well as various roles in drug development with other pharmaceutical companies. He received his doctorate in pharmacy from the University of Cincinnati and his bachelor's degree in pharmacy from the University of North Carolina at Chapel Hill. He is a graduate of the Owner President Management (OPM) program at Harvard Business School.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

CONTACT Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.com


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
7. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
8. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):